DC
SCLN

Davenport & Co’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Davenport & Co’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,400
Closed -$105K – 622
2015
Q4 		$105K Sell
11,400
-27,600
-71% -$231K ﹤0.01% 565
2015
Q3 		$271K Buy
39,000
+16,500
+73% +$141K ﹤0.01% 465
2015
Q2 		$221K Buy
+22,500
New +$205K ﹤0.01% 527

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Davenport & Co's SCLN Position: Q1 2016 in Review

Davenport & Co sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2016, closing a stake of 11,400 shares — an estimated $105K sold.

Davenport & Co first reported a position in SCLN in Q2 2015 and held it in 3 quarters. The position peaked at $271K in Q3 2015. 142 funds tracked by Wall St. Rank hold SCLN as of Q1 2016.

  • Davenport & Co reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Davenport & Co sold 11,400 Sciclone Pharmaceuticals Inc shares in Q1 2016, an estimated $105K.
  • Davenport & Co first reported a position in Sciclone Pharmaceuticals Inc in Q2 2015 and held it in 3 quarters.
  • Davenport & Co's Sciclone Pharmaceuticals Inc position peaked at $271K in Q3 2015.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2016.

Based on Davenport & Co's 13F filing for Q1 2016, filed 25 Apr 2016.